The University of Chicago Comprehensive Cancer Center (UCCCC) is submitting this competitive renewal application for its Cancer Center Support Grant for Years 38-42. The mission of the UCCCC is to elucidate the determinants of cancer, to develop cures for cancer, and to prevent cancer. Our cancer research programs emphasize translational and interdisciplinary research, and we pursue this goal by promoting collaboration among a diverse and dedicated team of outstanding basic, translational, clinical, and population researchers. The 210 members of the UCCCC are organized into six established programs, all with a translational focus (Molecular Mechanisms of Cancer; Hematopoiesis and Hematologic Malignancies; Immunology and Cancer; Pharmacogenomics and Experimental Therapeutics; Advanced Imaging; and Cancer Prevention and Control). Clinical research is a major focus of multidisciplinary activity at the UCCCC. In 2011, 876 individual patients were accrued to therapeutic protocols supported, in part, by NCI cooperative agreements and contracts to conduct Phase I, Phase II, and Phase III clinical trials. The UCCCC is a full member of the Alliance (formerly members of Cancer and Leukemia Group B and American College of Surgeons Oncology Group), the Gynecologic Oncology Group, and the Children's Oncology Group, and participates in the Radiation Therapy Oncology Group, and National Surgical Adjuvant Breast and Bowel Program studies. Funds are requested in this application for Senior Leaders and Program Leaders, Planning and Evaluation, Developmental Funds, Administration, Protocol-Specific Research, the Protocol Review and Monitoring System, Staff Investigators, and 11 shared resources (Biostatistics; Cancer Clinical Trials Office; Cytometry and Antibody Technology; Genomics; Human Immunologic Monitoring and cGMP; Human Tissue Resource Center; Image Computing, Analysis, and Repository; Integrated Microscopy; Integrated Small Animal Imaging Research Resource; Pharmacology; and Transgenic Mouse/Embryonic Stem Cell Facilities). In the period since the last review (2008-2011), the UCCCC has increased its peer-reviewed funding by 27% to $68.9 million in direct costs (NCI funding has increased by 17% from $18 to $21 million in direct costs), and contributed 1,850 peer-reviewed publications. Through an in-depth institutional review and multi-faceted strategic planning process, the UCCCC now has new and strong institutional commitments, and a stable and experienced leadership team, and has developed and implemented a comprehensive strategic plan, and restructured its Research Programs.

Public Health Relevance

The mission of the UCCCC is to elucidate the determinants of cancer, to develop cures for cancer, and to prevent cancer. In addition, we provide education and training for basic scientists, physicians, and clinical investigators, and local health professionals, as well as develop and implement community-based cancer education and outreach programs. Our mission is fulfilled in an environment that values diversity, the development of the next generation of physicians and scientists, and delivering comprehensive and compassionate patient care.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA014599-41S4
Application #
9340511
Study Section
Subcommittee A - Cancer Centers (NCI-A)
Program Officer
Shafik, Hasnaa
Project Start
1997-09-01
Project End
2018-03-31
Budget Start
2016-04-01
Budget End
2017-03-31
Support Year
41
Fiscal Year
2016
Total Cost
$749,765
Indirect Cost
$275,230
Name
University of Chicago
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
005421136
City
Chicago
State
IL
Country
United States
Zip Code
60637
Zeineddine, Hussein A; Girard, Romuald; Saadat, Laleh et al. (2018) Phenotypic characterization of murine models of cerebral cavernous malformations. Lab Invest :
Kane, Melissa; Deiss, Felicity; Chervonsky, Alexander et al. (2018) A Single Locus Controls Interferon Gamma-Independent Antiretroviral Neutralizing Antibody Responses. J Virol 92:
Xiao, Annie; Crosby, Jennie; Malin, Martha et al. (2018) Single-institution report of setup margins of voluntary deep-inspiration breath-hold (DIBH) whole breast radiotherapy implemented with real-time surface imaging. J Appl Clin Med Phys 19:205-213
Gamazon, Eric R; Trendowski, Matthew R; Wen, Yujia et al. (2018) Gene and MicroRNA Perturbations of Cellular Response to Pemetrexed Implicate Biological Networks and Enable Imputation of Response in Lung Adenocarcinoma. Sci Rep 8:733
Girard, Romuald; Zeineddine, Hussein A; Koskimäki, Janne et al. (2018) Plasma Biomarkers of Inflammation and Angiogenesis Predict Cerebral Cavernous Malformation Symptomatic Hemorrhage or Lesional Growth. Circ Res 122:1716-1721
Day, Kasey J; Casler, Jason C; Glick, Benjamin S (2018) Budding Yeast Has a Minimal Endomembrane System. Dev Cell 44:56-72.e4
Pu, Jinyue; Kentala, Kaitlin; Dickinson, Bryan C (2018) Multidimensional Control of Cas9 by Evolved RNA Polymerase-Based Biosensors. ACS Chem Biol 13:431-437
Pectasides, Eirini; Stachler, Matthew D; Derks, Sarah et al. (2018) Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma. Cancer Discov 8:37-48
Liu, Hongtao; Zha, Yuanyuan; Choudhury, Noura et al. (2018) WT1 peptide vaccine in Montanide in contrast to poly ICLC, is able to induce WT1-specific immune response with TCR clonal enrichment in myeloid leukemia. Exp Hematol Oncol 7:1
Nageeb, Shaheen; Vu, Milkie; Malik, Sana et al. (2018) Adapting a religious health fatalism measure for use in Muslim populations. PLoS One 13:e0206898

Showing the most recent 10 out of 668 publications